Literature DB >> 6794337

Serotype determinant protein of Neisseria Meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells.

T B Helting, G Guthöhrlein, F Blackkolb, H Ronneberger.   

Abstract

Neisseria meningitidis Group B microorganisms, inactivated with phenol and harvested by centrifugation, were subjected to direct treatment with various detergents to solubilize the serotype determinant proteins localized in the outer membrane. Analysis of the data showed that extraction of the cells with detergents provided yields of the serotype protein substantially exceeding those obtained by simple salt extraction of the bacteria. Routinely, more than 2 mg of end product per g of cell mass (wet weight) may be recovered by the present method. By gel chromatographic analysis, the serotype determinant protein was shown to interact with the capsular polysaccharides derived from Group A or C Neisseria meningitidis microorganisms, forming high molecular weight complexes. This interaction markedly enhanced the solubility of the serotype determinant protein. Combined vaccines of the type-specific protein with the group- specific polysaccharides were evaluated for their immunogenic potential in the subcutaneous steel spring implant model. In guinea pigs, amounts corresponding to 10 micrograms completely prevented infection upon challenge with homologous organisms four weeks after immunization. Partial protection was observed with immunizing doses corresponding to 2 micrograms or 0.4 micrograms/animal, respectively. Compared to lyophilized preparations, vaccines adsorbed to a mineral carrier were slightly less effective in inducing protection, whereas inclusion of Bordetella pertussis as a component of the vaccine stimulated the immune response.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794337

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Scand C        ISSN: 0304-1328


  7 in total

Review 1.  Bexsero® chronicle.

Authors:  George Vernikos; Duccio Medini
Journal:  Pathog Glob Health       Date:  2014-10       Impact factor: 2.894

2.  Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations.

Authors:  M S Peppler; C E Frasch
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

3.  Distribution of serotypes of Neisseria meningitidis in the Federal Republic of Germany, 1979-1981.

Authors:  U Berger
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

4.  Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.

Authors:  P P Vella; S Marburg; J M Staub; P J Kniskern; W Miller; A Hagopian; C Ip; R L Tolman; C M Rusk; L S Chupak
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

5.  Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

Authors:  W D Zollinger; R E Mandrell
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

Review 6.  Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.

Authors:  Johan Holst; Philipp Oster; Richard Arnold; Michael V Tatley; Lisbeth M Næss; Ingeborg S Aaberge; Yvonne Galloway; Anne McNicholas; Jane O'Hallahan; Einar Rosenqvist; Steven Black
Journal:  Hum Vaccin Immunother       Date:  2013-03-07       Impact factor: 3.452

7.  Product review on the IMD serogroup B vaccine Bexsero®.

Authors:  Ala-Eddine Deghmane; Muhamed-Kheir Taha
Journal:  Hum Vaccin Immunother       Date:  2022-02-22       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.